Mcnulty Korea Co., Ltd.

Mcnulty Korea Co., Ltd.

KKRX:222980
1,739.00
KRW
-18.00
(-1.02%)
-72.84EPS
21.71BMarket Cap
Mcnulty Korea Co., Ltd.
KRX:222980
(Korea Stock Exchange)

Recent

price

1,739.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
2,303.91
3,803.18
3,266.06
3,312.51
3,373.2
4,369.88
5,097.99
5,097.72
6,087.83
7,144.24
7,819.68
8,900.79
9,026.81
Revenue per Share
633.5
325
276
127
68.71
-108
454
177.85
-279
-310.11
7
-117
-38.57
Basic EPS, GAAP
120.82
88.07
-227.81
-395.78
-199
75.48
212.52
-214.15
-749.2
-107.99
-372.2
450.11
726.12
Free Cash Flow per Basic Share
- -
- -
49.99
65.1
25.26
- -
- -
49.44
27.25
- -
- -
- -
- -
Dividend per Share
1,089.97
2,562.14
2,776.34
2,836.25
2,773.11
2,768.78
3,326.19
3,502.81
3,401.42
3,112.29
3,244.91
3,085.95
3,736.18
Book Value per Share
1,077.1
2,548.72
2,761.53
2,819.83
2,713.09
2,698.73
3,261.38
3,126.18
3,037.32
2,746.45
2,883.31
2,733.89
3,365.76
Tangible Book Value per Share
8
7
10
10
10
10
10
10
12
11
11
11
11
Basic Weighted Avg Shares
19,421
27,131
32,505
32,907
33,220
42,844
49,065
53,410
70,215
78,400
88,832
96,310
97,262
Sales/Revenue/Turnover
3.49
10.16
11.41
6.17
2.23
4.9
6.8
3.02
-0.95
-5.34
0.13
-1.01
-1.25
Operating Margin (%)
1,225
1,271
1,380
1,538
1,915
3,042
3,150
3,432
3,687
3,904
3,856
3,780
3,800
Depreciation Expense
5,340
2,318
2,747
1,262
677
-1,059
4,369
1,863
-3,218
-3,403
80
-1,266
-416
Net Income, GAAP
18.12
8.1
27.64
- -
- -
- -
12.98
27.77
- -
- -
- -
- -
- -
Effective Tax Rate (%)
27.5
8.55
8.45
3.83
2.04
-2.47
8.91
3.49
-4.58
-4.34
0.09
-1.31
-0.43
Profit Margin (%)
2,371
15,267
13,120
10,334
3,830
11,900
24,277
20,397
18,253
5,617
10,614
5,957
15,038
Working Capital
2,958
2,379
2,440
4,567
2,167
7,106
10,913
13,299
14,409
5,906
6,311
808
8,271
LT Debt
10,845
25,493
27,625
28,221
30,093
30,333
38,387
40,666
41,539
37,513
38,205
37,166
46,112
Total Equity
- -
10.34
8.5
- -
- -
- -
5.87
1.76
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
10.28
9.03
- -
- -
- -
9.27
3.95
- -
- -
- -
- -
- -
Return on Capital (%)
- -
12.76
10.34
4.52
2.42
-3.84
14.09
5.24
-8.69
-9.52
0.23
-3.71
-1.12
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
34,885
35,500
34,564
LT Borrowings
507
437
8,066
LT Finance Leases
301
204
205
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
34,681
27,659
21,709

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
50,151
52,409
60,657
Cash, Cash Equivalents & STI
22,486
22,884
31,247
Accounts Receivable, Net
6,955
7,947
8,547
Inventories
19,702
20,451
19,432
Total Current Liabilities
44,194
45,693
45,619
Payables & Accruals
- -
- -
- -
ST Debt
34,885
35,500
34,564
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.2%
-0.5%
-2.72%
Free Cash Flow
-36.83%
6.14%
-215.19%
Net Income, GAAP
-296.97%
-423.73%
-1,692.02%
Sales/Revenue/Turnover
13.92%
14.74%
8.42%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
22,258
22,448
22,191
21,935
88,832
2025
24,551
24,946
24,767
22,046
96,310
2026
23,504
26,944
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11.08
80
-7
-77.45
7
2025
-27
-16
-57.68
-17.26
-117
2026
52.49
-16
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Mcnulty Korea Co., Ltd. is a South Korea-based comprehensive food, beverage, and healthcare company primarily engaged in the processing, manufacturing, and distribution of coffee and beverage products, alongside the contract manufacturing of pharmaceuticals and health functional foods. Founded in 1993 and headquartered in Cheonan, South Korea, the company operates across three principal business segments: Coffee and Beverages, Pharmaceuticals, and Health Functional Foods. In its core Coffee and Beverages segment, the company manufactures and markets a diverse lineup of roasted whole beans; ground coffee blends; single-serve drip bags; instant soluble coffee sticks; liquid beverage pouches; ready-to-drink canned coffees; and liquid tea concentrates, marketed under proprietary brands including iBrew, Happy Coffee, Horaengi, Tea Brew, God-sungbi, and the business-to-business line to-be Coffee, while additionally supplying original equipment manufacturing and original design manufacturing services to commercial retailers, hypermarkets, and food service operators. In its Pharmaceuticals segment, conducted through its subsidiary Mcnulty Pharma Co., Ltd., the company provides contract development and manufacturing organization, contract manufacturing organization, and contract sales organization services, producing generic prescription medications across multiple therapeutic categories including cardiovascular treatments for hypertension and hyperlipidemia; metabolic treatments for diabetes; gastrointestinal therapeutics; and antihistamines, as well as proprietary medical solutions such as EndoAlcom, an endoscopic submucosal dissection lifting agent. In its Health Functional Foods segment, operated through Mcnulty Bio Co., Ltd., the company manufactures and distributes dietary supplements, botanical extracts, and daily wellness formulations. In recent developments, Mcnulty Korea has accelerated product diversification and retail expansion by launching the Horaengi canned latte series, ultra-large capacity 2.1-liter liquid pouch beverages, and single-serve Tea Brew liquid tea sticks distributed through major national convenience store chains, alongside debuting its cost-effective God-sungbi brand and dedicated to-be commercial coffee brand. To expand its geographic footprint, the company received the Seven Million Dollar Export Tower honor in recognition of growing international shipments across overseas retail and food service channels. Concurrently, the pharmaceutical division has expanded commercialization efforts for EndoAlcom, pursuing innovative medical device designation and ramping up contract manufacturing capacity to support long-term healthcare revenue targets across clinical and hospital markets.